Juliette Mb Hukin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6571968/publications.pdf

Version: 2024-02-01

105 papers 4,590 citations

35 h-index 106344 65 g-index

109 all docs

109 docs citations

109 times ranked 5500 citing authors

#	Article	IF	CITATIONS
1	Treatment-responsive Holmes tremor in a child with low-pressure hydrocephalus: video case report and systematic review of the literature. Journal of Neurosurgery: Pediatrics, 2022, 29, 520-527.	1.3	2
2	Lowâ€grade diffusely infiltrative tumour (LGDIT), SMARCB1â€mutant: A clinical and histopathological distinct entity showing epigenetic similarity with ATRTâ€MYC. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	5
3	ATRT-07. Low-grade diffusely infiltrative tumor, SMARCB1-mutant: a clinical and histopathological distinct entity showing epigenetic similarity with ATRT-MYC. Neuro-Oncology, 2022, 24, i3-i4.	1.2	O
4	NFB-08. TRAM-01: A Phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas. Neuro-Oncology, 2022, 24, i129-i129.	1.2	2
5	MEDB-49. Relapsed SHH medulloblastomas in young children. Are there alternatives to full-dose craniospinal irradiation?. Neuro-Oncology, 2022, 24, i117-i117.	1.2	O
6	A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway Journal of Clinical Oncology, 2022, 40, 2042-2042.	1.6	2
7	A case series of pediatric survivors of anaplastic pleomorphic xanthoastrocytoma. Neuro-Oncology Advances, 2021, 3, vdaa176.	0.7	1
8	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	1.6	40
9	Histologic Correlates of Molecular Group 4 Pediatric Medulloblastoma: A Retrospective Canadian Review. Pediatric and Developmental Pathology, 2021, 24, 309-317.	1.0	2
10	Trametinib therapy for children with neurofibromatosis type 1 and lifeâ€threatening plexiform neurofibroma or treatmentâ€refractory lowâ€grade glioma. Cancer Medicine, 2021, 10, 3556-3564.	2.8	17
11	Multiâ€institutional analysis of treatment modalities in basal ganglia and thalamic germinoma. Pediatric Blood and Cancer, 2021, 68, e29172.	1.5	3
12	Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. Science Translational Medicine, 2021, 13, eabc0497.	12.4	29
13	CTNI-06. TRAM-01: A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. Neuro-Oncology, 2021, 23, vi59-vi60.	1.2	1
14	Intracranial Germ Cell Tumors in Adolescents and Young Adults: A 40-Year Multi-Institutional Review of Outcomes. International Journal of Radiation Oncology Biology Physics, 2020, 106, 269-278.	0.8	38
15	Long term toxicity of intracranial germ cell tumor treatment in adolescents and young adults. Journal of Neuro-Oncology, 2020, 149, 523-532.	2.9	14
16	Pontine gliomas a 10-year population-based study: a report from The Canadian Paediatric Brain Tumour Consortium (CPBTC). Journal of Neuro-Oncology, 2020, 149, 45-54.	2.9	8
17	Canadian Pediatric Neuro-Oncology Standards of Practice. Frontiers in Oncology, 2020, 10, 593192.	2.8	13
18	Factors influencing cognitive outcome in opsoclonus–myoclonus syndrome. Developmental Medicine and Child Neurology, 2020, 62, 1349-1349.	2.1	0

#	Article	IF	CITATIONS
19	Cancer and Tumor-Associated Childhood Stroke: Results From the International Pediatric Stroke Study. Pediatric Neurology, 2020, 111, 59-65.	2.1	7
20	Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nature Medicine, 2020, 26, 720-731.	30.7	141
21	Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature. Journal of Neuro-Oncology, 2020, 147, 721-730.	2.9	21
22	Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on "Head Start―III: a multi-institutional, prospective clinical trial. Neuro-Oncology, 2020, 22, 1862-1872.	1.2	57
23	Pontine Embryonal Tumor With Multilayered Rosettes: An Autopsy Case Exhibiting Extensive Posttreatment Clial and Neuronal Maturation. Pediatric and Developmental Pathology, 2020, 23, 326-331.	1.0	2
24	NFB-12. TRAMETINIB THERAPY FOR PEDIATRIC PATIENTS WITH REFRACTORY LOW GRADE GLIOMA OR EXTENSIVE SYMPTOMATIC PLEXIFORM NEUROFIBROMA. Neuro-Oncology, 2020, 22, iii420-iii420.	1.2	0
25	HGG-35. PEDIATRIC PLEOMORPHIC XANTHOASTROCYTOMA WITH ANAPLASIA TREATED WITH SURGERY AND ADJUVANT CHEMOTHERAPY: A CASE SERIES OF 3 LONG-TERM SURVIVORS. Neuro-Oncology, 2020, 22, iii350-iii350.	1.2	0
26	LGG-19. SPINAL LOW-GRADE GLIOMAS IN CANADIAN CHILDREN: A MULTI-CENTRE RETROSPECTIVE REVIEW. Neuro-Oncology, 2020, 22, iii369-iii370.	1.2	0
27	LGG-25. A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. TRAM-01. Neuro-Oncology, 2020, 22, iii371-iii371.	1.2	1
28	GCT-23. MULTI-INSTITUTIONAL ANALYSIS OF TREATMENT MODALITIES IN BASAL GANGLIA AND THALAMIC GERMINOMA. Neuro-Oncology, 2020, 22, iii332-iii332.	1.2	0
29	Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. Journal of Clinical Oncology, 2019, 37, 974-983.	1.6	154
30	Canadian patterns of practice for intracranial germ cell tumors in adolescents and young adults. Journal of Neuro-Oncology, 2019, 143, 289-296.	2.9	8
31	A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. BMC Cancer, 2019, 19, 1250.	2.6	93
32	Narcolepsy and Hypothalamic Region Tumors: Presentation and Evolution. Pediatric Neurology, 2018, 84, 27-31.	2.1	16
33	Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience. Pediatric Blood and Cancer, 2018, 65, e26988.	1.5	51
34	A randomized control intervention trial to improve social skills and quality of life in pediatric brain tumor survivors. Psycho-Oncology, 2018, 27, 91-98.	2.3	54
35	GERM-23. INTRACRANIAL GROWING TERATOMA SYNDROME (IGTS): AN INTERNATIONAL RETROSPECTIVE STUDY. Neuro-Oncology, 2018, 20, i88-i88.	1.2	0
36	IMMU-08. PHASE I TRIAL (NCT02457845) SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF IMMUNOVIROTHERAPY WITH HSV G207 IN CHILDREN WITH PROGRESSIVE MALIGNANT SUPRATENTORIAL BRAIN TUMORS. Neuro-Oncology, 2018, 20, i100-i100.	1.2	2

#	Article	IF	CITATIONS
37	Early changes in white matter predict intellectual outcome in children treated for posterior fossa tumors. NeuroImage: Clinical, 2018, 20, 697-704.	2.7	15
38	Canadian Patterns of Practice for Intracranial Germ Cell Tumors in Adolescents and Young Adults. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1009.	0.8	0
39	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	7.7	86
40	Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature. Journal of Neuro-Oncology, 2017, 132, 155-162.	2.9	43
41	Longitudinal Outcomes in the 2014 Acute Flaccid Paralysis Cluster in Canada. Journal of Child Neurology, 2017, 32, 301-307.	1.4	50
42	Determinants of social competence in pediatric brain tumor survivors who participated in an intervention study. Supportive Care in Cancer, 2017, 25, 2891-2898.	2.2	13
43	Opsoclonus-Myoclonus Syndrome: A New Era of Improved Prognosis?. Pediatric Neurology, 2017, 72, 65-69.	2.1	29
44	Determinants of quality of life outcomes for survivors of pediatric brain tumors. Pediatric Blood and Cancer, 2017, 64, e26481.	1.5	18
45	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathologica, 2017, 134, 705-714.	7.7	168
46	MB-91OUTCOMES FOR YOUNG CHILDREN WITH BRAIN TUMOURS TREATED ACCORDING TO THE HEAD START PROTOCOLS: A SINGLE-CENTRE EXPERIENCE. Neuro-Oncology, 2016, 18, iii117.4-iii118.	1.2	0
47	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	16.8	191
48	Eye Findings on Vigabatrin and Taurine Treatment in Two Patients with Succinic Semialdehyde Dehydrogenase Deficiency. Neuropediatrics, 2016, 47, 263-267.	0.6	11
49	White matter and information processing speed following treatment with cranial-spinal radiation for pediatric brain tumor Neuropsychology, 2016, 30, 425-438.	1.3	42
50	Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. Acta Neuropathologica Communications, 2016, 4, 93.	5.2	100
51	Phase II Weekly Vinblastine for Chemotherapy-NaÃ-ve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. Journal of Clinical Oncology, 2016, 34, 3537-3543.	1.6	157
52	Episodic ataxia associated with a de novo SCN2A mutation. European Journal of Paediatric Neurology, 2016, 20, 772-776.	1.6	26
53	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	1.6	160
54	Ophthalmological outcomes of patients treated for pineal region tumors. Journal of Neurosurgery: Pediatrics, 2016, 17, 558-563.	1.3	17

#	Article	IF	CITATIONS
55	Pediatric thalamic tumors in the MRI era: a Canadian perspective. Child's Nervous System, 2016, 32, 269-280.	1.1	37
56	AT-07 * SUCCESSFUL TREATMENT OF ATRT PATIENTS WITHOUT ADJUVANT RADIATION: A MULTI INSTITUTIONAL CANADIAN EXPERIENCE. Neuro-Oncology, 2015, 17, iii2-iii2.	1.2	0
57	Neurocognitive evaluation of long term survivors of atypical teratoid rhabdoid tumors (ATRT): The Canadian registry experience. Pediatric Blood and Cancer, 2015, 62, 1265-1269.	1.5	29
58	EZH2 expression is a prognostic factor in childhood intracranial ependymoma: A Canadian Pediatric Brain Tumor Consortium study. Cancer, 2015, 121, 1499-1507.	4.1	30
59	Intracystic interferon-α treatment leads to neurotoxicity in craniopharyngioma: case report. Journal of Neurosurgery: Pediatrics, 2015, 16, 301-304.	1.3	14
60	The role of resection alone in select children with intracranial ependymoma: the Canadian Pediatric Brain Tumour Consortium experience. Child's Nervous System, 2015, 31, 57-65.	1.1	19
61	Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncology, The, 2015, 16, 569-582.	10.7	147
62	Assessing the accuracy of death records and pre-mortem clinical diagnoses in children diagnosed with brain tumors: A retrospective chart review of children in British Columbia, Canada. Pathology Research and Practice, 2015, 211, 748-753.	2.3	2
63	White matter compromise predicts poor intellectual outcome in survivors of pediatric low-grade glioma. Neuro-Oncology, 2015, 17, 604-613.	1.2	36
64	Outcome of neurofibromatosis type 1 patients treated with first line vinblastine for optic pathway gliomas: A Canadian multicenter study Journal of Clinical Oncology, 2015, 33, 2019-2019.	1.6	1
65	Deâ€escalation of therapy for pediatric medulloblastoma: Tradeâ€offs between quality of life and survival. Pediatric Blood and Cancer, 2014, 61, 1300-1304.	1.5	21
66	Changes to Memory Structures in Children Treated for Posterior Fossa Tumors. Journal of the International Neuropsychological Society, 2014, 20, 168-180.	1.8	59
67	Multimodality therapy for CNS mixed malignant germ cell tumors (MMGCT): results of a phase II multi-institutional study. Journal of Neuro-Oncology, 2014, 118, 93-100.	2.9	21
68	Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature Genetics, 2014, 46, 451-456.	21.4	525
69	Growing teratoma syndrome in intracranial non-germinomatous germ cell tumors (iNGGCTs): a risk for secondary malignant transformation—a report of two cases. Child's Nervous System, 2014, 30, 953-957.	1.1	13
70	Late effects in survivors of childhood CNS tumors treated on Head Start I and II protocols. Pediatric Blood and Cancer, 2014, 61, 1644-1672.	1.5	46
71	Pleomorphic xanthoastrocytoma of the spinal cord: case report and literature review., 2014, 33, 190-196.		17
72	Epidemiology of malignant pontine gliomas (MPG) in the paediatric population in Canada: A study of the Canadian paediatric brain tumour consortium (CPBTC). Canadian Journal of Neurological Sciences, 2014, 41, S16-S16.	0.5	0

#	Article	IF	Citations
73	Novel Mutations in <i>FA2H</i> -Associated Neurodegeneration. Journal of Child Neurology, 2013, 28, 1500-1504.	1.4	25
74	Optic pathway gliomas in adolescencetime to challenge treatment choices?. Neuro-Oncology, 2013, 15, 391-400.	1.2	27
75	Weekly vinblastine in chemotherapy-naive children with unresectable or progressive low grade glioma: A Canadian cooperative study Journal of Clinical Oncology, 2013, 31, 10029-10029.	1.6	2
76	Pharmacogenomics of vincristineâ€induced neurotoxicity in pediatric cancer patients. FASEB Journal, 2013, 27, 666.3.	0.5	0
77	Clinical and neuroanatomical predictors of cerebellar mutism syndrome. Neuro-Oncology, 2012, 14, 1294-1303.	1.2	112
78	Atypical Teratoid Rhabdoid Tumors (ATRTs): The British Columbia's Children's Hospital's Experience, 1986–2006. Brain Pathology, 2012, 22, 625-635.	4.1	29
79	Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma. Journal of Clinical Oncology, 2012, 30, 1358-1363.	1.6	198
80	Intracranial tumors in infants: long-term functional outcome, survival, and its predictors. Child's Nervous System, 2012, 28, 547-555.	1.1	21
81	Supratentorial Primitive Neuroectodermal Tumors. , 2012, , 15-24.		0
82	Cerebello–thalamo–cerebral connections in pediatric brain tumor patients: Impact on working memory. NeuroImage, 2011, 56, 2238-2248.	4.2	99
83	Late mortality in pediatric patients with craniopharyngioma. Journal of Neuro-Oncology, 2010, 100, 105-111.	2.9	63
84	Intracystic treatments for craniopharyngioma. Neurosurgical Focus, 2010, 28, E13.	2.3	66
85	A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. European Journal of Cancer, 2010, 46, 3271-3279.	2.8	43
86	A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. European Journal of Cancer, 2009, 45, 2352-2359.	2.8	34
87	Occurrence of Basal Ganglia Germ Cell Tumors Without a Mass. Archives of Neurology, 2009, 66, 789-92.	4. 5	5
88	Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): Report of the Head Start I and II experience. Pediatric Blood and Cancer, 2008, 50, 312-318.	1.5	125
89	Carboplatin hypersensitivity reaction in pediatric patients with lowâ€grade glioma. Cancer, 2008, 112, 892-899.	4.1	77
90	Atypical Presentation of Basal Ganglia Germ Cell Tumors in Children. Journal of Neurosurgery: Pediatrics, 2008, 1, A353-A353.	1.3	1

#	Article	IF	Citations
91	Intracystic bleomycin therapy for craniopharyngioma in children. Cancer, 2007, 109, 2124-2131.	4.1	89
92	Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatric Blood and Cancer, 2007, 49, 34-40.	1.5	104
93	Outcome of secondary high-grade glioma in children previously treated for a malignant condition: A study of the Canadian Pediatric Brain Tumour Consortium. Radiotherapy and Oncology, 2006, 81, 33-38.	0.6	41
94	Distinctive clinical course and pattern of relapse in adolescents with medulloblastoma. International Journal of Radiation Oncology Biology Physics, 2006, 64, 402-407.	0.8	35
95	Medulloblastoma in the second decade of life: A specific group with respect to toxicity and management. Cancer, 2005, 103, 1874-1880.	4.1	61
96	Childhood craniopharyngioma: Vancouver experience. Child's Nervous System, 2005, 21, 758-765.	1.1	24
97	Asynchronous burst-suppression in a child with callosal Ki-1 anaplastic large cell lymphoma. Neurology, 2005, 65, 947-949.	1.1	2
98	Malaysian Siblings with Friedreich Ataxia and Chorea: A Novel Deletion in the Frataxin Gene. Canadian Journal of Neurological Sciences, 2004, 31, 383-386.	0.5	23
99	Leptomeningeal dissemination at diagnosis of pediatric low-grade neuroepithelial tumors. Neuro-Oncology, 2003, 5, 188-196.	1.2	27
100	Leptomeningeal dissemination in children with progressive low-grade neuroepithelial tumors. Neuro-Oncology, 2002, 4, 253-260.	1.2	48
101	Intratumoral Therapy with Bleomycin for Cystic Craniopharyngiomas in Children. Pediatric Neurosurgery, 2000, 33, 211-218.	0.7	92
102	Treatment of Intracranial Ependymoma by Surgery Alone. Pediatric Neurosurgery, 1998, 29, 40-45.	0.7	117
103	Clinical Manifestations of Childhood Ependymoma: A Multitude of Syndromes. Pediatric Neurosurgery, 1998, 28, 49-55.	0.7	65
104	Acute Swelling of the Cerebellum in Childhood. Journal of Child Neurology, 1997, 12, 273-275.	1.4	0
105	Reye syndrome associated with subclinical varicella zoster virus and influenza a infection. Pediatric Neurology, 1993, 9, 134-136.	2.1	6